Sarah R Preis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10463388/publications.pdf

Version: 2024-02-01

489802 799663 2,272 21 18 21 citations h-index g-index papers 21 21 21 5361 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	New biomarkers from multiomics approaches: improving risk prediction of atrial fibrillation. Cardiovascular Research, 2021, 117, 1632-1644.	1.8	12
2	Protein Biomarkers and Risk of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007607.	2.1	31
3	Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005918.	0.9	14
4	Distribution of cerebral microbleeds in the East and West. Neurology, 2019, 92, e1086-e1097.	1.5	53
5	Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ: British Medical Journal, 2018, 361, k1453.	2.4	232
6	Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation. Circulation, 2018, 137, 1027-1038.	1.6	196
7	Baseline White Matter Hyperintensities and Hippocampal Volume are Associated With Conversion From Normal Cognition to Mild Cognitive Impairment in the Framingham Offspring Study. Alzheimer Disease and Associated Disorders, 2018, 32, 50-56.	0.6	56
8	Cerebral Microbleeds as Predictors of Mortality. Stroke, 2017, 48, 781-783.	1.0	19
9	Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study. Alzheimer's and Dementia, 2017, 13, 1327-1336.	0.4	93
10	Clinical and Environmental Correlates of Serum BDNF: A Descriptive Study with Plausible Implications for AD Research. Current Alzheimer Research, 2017, 14, 722-730.	0.7	12
11	Neuropsychological Criteria for Mild Cognitive Impairment and Dementia Risk in the Framingham Heart Study. Journal of the International Neuropsychological Society, 2016, 22, 937-943.	1.2	98
12	Circulating biomarkers and incident ischemic stroke in the Framingham Offspring Study. Neurology, 2016, 87, 1206-1211.	1.5	38
13	Carotid Atherosclerosis and Cerebral Microbleeds: The Framingham Heart Study. Journal of the American Heart Association, 2016, 5, e002377.	1.6	41
14	Long-Term Exposure to Fine Particulate Matter, Residential Proximity to Major Roads and Measures of Brain Structure. Stroke, 2015, 46, 1161-1166.	1.0	198
15	Inflammatory biomarkers, cerebral microbleeds, and small vessel disease. Neurology, 2015, 84, 825-832.	1.5	171
16	Associations of Circulating Growth Differentiation Factor-15 and ST2 Concentrations With Subclinical Vascular Brain Injury and Incident Stroke. Stroke, 2015, 46, 2568-2575.	1.0	54
17	Gender and incidence of dementia in the Framingham Heart Study from midâ€adult life. Alzheimer's and Dementia, 2015, 11, 310-320.	0.4	277
18	Risk Factors, Stroke Prevention Treatments, and Prevalence of Cerebral Microbleeds in the Framingham Heart Study. Stroke, 2014, 45, 1492-1494.	1.0	213

SARAH R PREIS

#	Article	IF	CITATIONS
19	Serum Brain-Derived Neurotrophic Factor and the Risk for Dementia. JAMA Neurology, 2014, 71, 55.	4.5	219
20	Development and validation of a brief dementia screening indicator forÂprimary care. Alzheimer's and Dementia, 2014, 10, 656.	0.4	114
21	Serum Brain–Derived Neurotrophic Factor and Vascular Endothelial Growth Factor Levels Are Associated With Risk of Stroke and Vascular Brain Injury. Stroke, 2013, 44, 2768-2775.	1.0	131